ASH 2025 | Transplant outcomes in B-ALL treated with inotuzumab ozogamicin with mini-hyper-CVD-based chemo-IO

The idea of this study comes from the fact that inotuzumab ozogamicin or inotuzumab ozogamicin is still not easily accessible in India. It comes quite costly, it’s still not very cheap. And we just thought that if we could combine inotuzumab ozogamicin with a low-dose chemotherapy and if then the patients could be taken for transplant and if and to see how they fare so it was basically a retrospective study we started the study somewhere in 2021 and the pace has been sort of a little slow but still we have been able to follow this protocol for about 24 patients. And we have been doing quite well with this. You know, we’ve not seen any mortality with this salvage chemotherapy per se. So we included about 24 patients and we were able to take about 21 patients to transplant. About 71% of the patients underwent a haploidentical transplant because a lot of patients, we do by about day 15 or 16 or so. The bacterial infection rates were quite manageable. Most of them were about grade 1 and 2. Few of them were grade 3. A significant proportion of patients developed veno-occlusive disease, which could be because of a lot of undiagnosed fatty liver and hepatic steatosis in our patients. The acute and chronic GvHD rates were quite low. And following a transplant, most of the patients were doing well at about one and two years. We have a decent follow-up with a median follow-up time of about 24 months. And this protocol has worked quite well for us. And this has been our go-to protocol, considering the fact that blinatumomab is not available to us as of now. Patients could reach a CR very quickly with this. And hence, this has been quite an effective protocol for us ever since we have started this.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.